Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.
Hum Vaccin ImmunotherJul 2, 2026 (epub)
Vivek Shinde, Wayne Woo, Anthony M Marchese et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1/2 randomized controlled trial evaluated the safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) in 637 previously vaccinated participants. The CIC vaccine induced comparable antibody responses against both influenza and SARS-CoV-2 strains, with similar safety profiles to standalone vaccines. Severe unsolicited adverse events were infrequent and not linked to the vaccine.
Key findings
- CIC formulations induced antibody responses against homologous and heterologous strains comparable to reference vaccines.
- The incidence of solicited and unsolicited adverse events was similar between CIC and reference groups.
- Severe unsolicited adverse events occurred infrequently in the CIC group but were not related to the vaccine.
Why it matters
The development of a combination vaccine targeting both influenza and SARS-CoV-2 could enhance public health responses to seasonal infections, potentially simplifying vaccination strategies and improving coverage.